Sheila Annie Peters

Icahn School of Medicine at Mount Sinai

Papers

1

Total Citations

38

H-Index

1

About

Sheila Annie Peters is a distinguished researcher whose work bridges the frontiers of cancer biology and assay automation. Her key research areas include DNA damage response mechanisms, particularly the quantification of ionizing radiation-induced double-strand breaks, and the development of high-throughput immunocytochemistry platforms. Her most notable contribution is the pioneering "Development of an Automated γ-H2AX Immunocytochemistry Assay" (2009, 38 citations), which introduced a significantly automated method to quantify gamma-H2AX—a critical biomarker for DNA damage. This work, conducted using PC-3 and DU145 prostate cancer cells, has broad applications in assessing physiological responses to radiation exposure, offering a scalable tool for both basic radiobiology and clinical screening. By transforming a traditionally manual, labor-intensive process into an automated, reproducible assay, Peters has enabled more efficient evaluation of radiation effects and potential therapeutic interventions. Her achievement stands as a vital resource for researchers studying genomic instability and cancer treatment efficacy, demonstrating her impact in advancing translational methodologies that empower the scientific community.

Research Focus

Key Achievements

1
H-Index
1
Papers
38
Total Citations
38
Avg Citations/Paper
🏆 Most Cited Paper
Development of an Automated γ-H2AX Immunocytochemistry Assay
38 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Icahn School of Medicine at Mount Sinai

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago